What is Ketotifen?
Ketotifen is an anti-allergy medication used to minimize the frequency and severity of asthma attacks. It works by blocking a chemical (histamine) that may lead to swelling(inflammation).
Ketotifen is commonly used in Canada, Europe, and Mexico to treat various allergies and asthma. Ketotifen is only commercially available as an ophthalmic drop in the United States. This is when Pavilion Compounding Pharmacy can help our patients and providers!
Working with your physician, our highly trained pharmacists can formulate and compound an oral Ketotifen capsule (dye and preservative free, veggie capsules also available). The typical dose used for asthma is 1mg capsules taken twice daily. For younger children (up to 3 years old), the starting dose is typically 0.5mg twice daily.
Compounding Ketotifen capsules does require a prescription from a licensed provider. If you need suggestions on providers who are familiar with this treatment option, please give Pavilion Compounding Pharmacy a call or e-mail.
Pavilion Compounding Pharmacy formulates Ketotifen into several different strengths and dosage forms. Oral capsules, liquid solutions, troches, lollipops, or tablet triturates are available. Several considerations must be made when selecting a compounding pharmacy, such as staff experience and training, equipment, and accreditation with PCAB. Also, complete and uniform mixing of the powder mixture: Our resonant acoustic mixer, or RAM, provides state of the art compounding mixing necessary to provide medication uniformity, especially when dealing with low doses.
Pavilion Compounding Pharmacy is accredited by the Pharmacy Compounding Accreditation Board (PCAB). In business since 1999, we look forward to working with our patients and providers to find solutions for complex medical conditions. Please contact one of our 5 pharmacists on staff to discuss treatment options!
1. https://www.medicinenet.com/ketotifen-oral_tablet/article.htm Retrieved April 4, 2019.
2.National Heart, Lung, and Blood Institute. Asthma. Retrieved April 4, 2019, from https://www.nhlbi.nih.gov/health-topics/asthma
3.Patterson R, Fitzsimons EJ, Choy AC, Harris KE. Malignant and corticosteroid-dependent idiopathic anaphylaxis: successful responses to ketotifen. Ann Allergy Asthma Immunol. 1997;79(2):138.